Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
13 Nov 2023
13 Nov 2023
Historique:
accepted:
09
10
2023
medline:
13
11
2023
pubmed:
13
11
2023
entrez:
13
11
2023
Statut:
aheadofprint
Résumé
Sotrovimab 500 mg administered by a single intravenous (IV) infusion has been granted special approval for emergency use in Japan for treatment of SARS-CoV-2 infection in adults and children aged ≥ 12 years weighing ≥ 40 kg. This Phase 1, single-dose study investigated the pharmacokinetics, safety, and tolerability of IV or intramuscular (IM) sotrovimab 500 mg doses versus placebo in healthy Japanese and Caucasian volunteers. This was a two-part, Phase 1, randomized, placebo-controlled, single-blind study. In Part 1, participants received a single sotrovimab 500 mg IV infusion or matching placebo on Day 1. In Part 2, participants received a single sotrovimab 500 mg IM dose or matching placebo on Day 1, administered as two 4 mL injections. There was no effect of ethnicity on the peak or total serum exposure of IV sotrovimab through Week 18; after adjusting for body weight, the point estimate and 90 % confidence interval for the ratio of total exposure between Japanese and Caucasian participants fell within conventional bioavailability bounds (80-125%). Geometric mean C After adjusting for body weight, exposures following a single IV dose of sotrovimab 500 mg were similar between Japanese and Caucasian participants, and higher in Japanese participants following IM administration. Higher exposures were not associated with any safety signals. ClinicalTrials.Gov: NCT04988152.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Sotrovimab 500 mg administered by a single intravenous (IV) infusion has been granted special approval for emergency use in Japan for treatment of SARS-CoV-2 infection in adults and children aged ≥ 12 years weighing ≥ 40 kg. This Phase 1, single-dose study investigated the pharmacokinetics, safety, and tolerability of IV or intramuscular (IM) sotrovimab 500 mg doses versus placebo in healthy Japanese and Caucasian volunteers.
METHODS
METHODS
This was a two-part, Phase 1, randomized, placebo-controlled, single-blind study. In Part 1, participants received a single sotrovimab 500 mg IV infusion or matching placebo on Day 1. In Part 2, participants received a single sotrovimab 500 mg IM dose or matching placebo on Day 1, administered as two 4 mL injections.
RESULTS
RESULTS
There was no effect of ethnicity on the peak or total serum exposure of IV sotrovimab through Week 18; after adjusting for body weight, the point estimate and 90 % confidence interval for the ratio of total exposure between Japanese and Caucasian participants fell within conventional bioavailability bounds (80-125%). Geometric mean C
CONCLUSIONS
CONCLUSIONS
After adjusting for body weight, exposures following a single IV dose of sotrovimab 500 mg were similar between Japanese and Caucasian participants, and higher in Japanese participants following IM administration. Higher exposures were not associated with any safety signals.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.Gov: NCT04988152.
Identifiants
pubmed: 37955825
doi: 10.1007/s40262-023-01319-2
pii: 10.1007/s40262-023-01319-2
doi:
Banques de données
ClinicalTrials.gov
['NCT04988152']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Gebru AA, Birhanu T, Wendimu E, et al. Global burden of COVID-19: situational analysis and review. Hum Antibodies. 2021;29(2):139–48. https://doi.org/10.3233/HAB-200420 .
doi: 10.3233/HAB-200420
pubmed: 32804122
Monteiro Pires S, Wyper GMA, Wengler A, et al. Burden of disease of COVID-19: strengthening the collaboration for national studies. Front Public Health. 2022;10:907012. https://doi.org/10.3389/fpubh.2022.907012 .
doi: 10.3389/fpubh.2022.907012
European Centre for Disease Prevention and Control. Risk factors and risk groups. 2022. https://www.ecdc.europa.eu/en/covid-19/latest-evidence/risk-factors-risk-groups . Accessed 11 May 2023.
World Health Organization. WHO Coronavirus (COVID-19) dashboard: global vaccination data. 2022. https://covid19.who.int . Accessed 11 May 2023.
World Health Organization. WHO Coronavirus (COVID-19) dashboard: Japan vaccination data. 2022. https://covid19.who.int/region/wpro/country/jp . Accessed 11 May 2023.
Hwang Y-C, Lu R-M, Su S-C, et al. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J Biomed Sci. 2022;29(1):1. https://doi.org/10.1186/s12929-021-00784-w .
doi: 10.1186/s12929-021-00784-w
pubmed: 34983527
pmcid: 8724751
Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1236–46. https://doi.org/10.1001/jama.2022.2832 .
doi: 10.1001/jama.2022.2832
pubmed: 35285853
pmcid: 8922199
Hirsch C, Park YS, Piechotta V, et al. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database Syst Rev. 2022;6(6):CD014945. https://doi.org/10.1002/14651858.CD014945.pub2 .
Pinto D, Park Y-J, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290–5. https://doi.org/10.1038/s41586-020-2349-y .
doi: 10.1038/s41586-020-2349-y
pubmed: 32422645
Cathcart AL, Havenar-Daughton C, Lempp FA, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. Preprint posted online April 1, 2022. https://doi.org/10.1101/2021.03.09.434607 .
Ko S-Y, Pegu A, Rudicell RS, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 2014;514(7524):642–5. https://doi.org/10.1038/nature13612 .
doi: 10.1038/nature13612
pmcid: 4433741
Zalevsky J, Chamberlain AK, Horton HM, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol. 2010;28(2):157–9. https://doi.org/10.1038/nbt.1601 .
doi: 10.1038/nbt.1601
pubmed: 20081867
pmcid: 2855492
Gaudinski MR, Coates EE, Houser KV, et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults. PLoS Med. 2018;15(1):e1002493. https://doi.org/10.1371/journal.pmed.1002493 .
doi: 10.1371/journal.pmed.1002493
pubmed: 29364886
pmcid: 5783347
Shapiro AE, Sarkis E, Acloque J, et al. Intramuscular versus intravenous SARS-CoV-2 neutralizing antibody sotrovimab for treatment of COVID-19 (COMET-TAIL): a randomized non-inferiority clinical trial. Open Forum Infect Dis. 2023;10(8):ofad354. https://doi.org/10.1093/ofid/ofad354 .
Okamasa A, Okour M, Austin D, et al. Safety and pharmacokinetic evaluation of anti-SARS-CoV-2 monoclonal antibody sotrovimab in Japanese/Caucasian healthy adults during intravenous infusion. Kansenshogaku zasshi. 2022;96(2):39–45. https://doi.org/10.11150/kansenshogakuzasshi.96.39 (article in Japanese).
Chiba K, Yoshitsugu H, Kyosaka Y, et al. A comprehensive review of the pharmacokinetics of approved therapeutic monoclonal antibodies in Japan: are Japanese phase I studies still needed? J Clin Pharmacol. 2014;54(5):483–94. https://doi.org/10.1002/jcph.231 .
doi: 10.1002/jcph.231
pubmed: 24242979
Bender Ignacio RA, Wohl DA, Arends W, et al. Comparative pharmacokinetics of tixagevimab/cilgavimab (AZD7442) administered intravenously versus intramuscularly in symptomatic SARS-CoV-2 infection. Clin Pharmacol Ther. 2022;112(6):1207–13. https://doi.org/10.1002/cpt.2706 .
doi: 10.1002/cpt.2706
pubmed: 35797235
Zuidema J, Pieters FAJM, Duchateau GSMJE. Release and absorption rate aspects of intramuscularly injected pharmaceuticals. Int J Pharm. 1988;47(1–3):1–12. https://doi.org/10.1016/0378-5173(88)90209-8 .
Larkin TA, Ashcroft E, Hickey BA, Elgellaie A. Influence of gender, BMI and body shape on theoretical injection outcome at the ventrogluteal and dorsogluteal sites. J Clin Nurs. 2018;27(1–2):e242–50. https://doi.org/10.1111/jocn.13923 .
doi: 10.1111/jocn.13923
pubmed: 28618093
Gupta AK, Perez-Rodríguez MT, Gonzalez-Rojas Y, et al. Safety, tolerability, and viral pharmacodynamics of the IgG monoclonal antibody sotrovimab administered via intramuscular injection for the treatment of early mild-to-moderate COVID-19. Open Forum Infect Dis. 2022;9(Suppl 2):ofac492.992. https://doi.org/10.1093/ofid/ofac492.992 .